Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EHSG KF - CUTISS

Next Previous
Drug Profile

EHSG KF - CUTISS

Alternative Names: denovoSkin™; EHSG-KF

Latest Information Update: 26 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CUTISS
  • Class Skin disorder therapies; Tissue transplantation therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Burns
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Burns

Most Recent Events

  • 16 Dec 2024 CUTISS plans a phase III trial for Burns (In children, In adolescents, In adults), in December 2024 (NCT06745557)
  • 05 Dec 2023 EHSG KF receives Orphan Drug status for Burns in European Union before December 2023 (Cutiss Website, December 2023)
  • 05 Dec 2023 EHSG KF receives Orphan Drug status for Burns in Switzerland before December 2023 (Cutiss Website, December 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top